# Invasive Bladder Cancer With Peritoneal Invasion and Rectal Involvement Causing Rectal, Bilateral Ureteral, and Common Bile Duct Obstruction Without a Retroperitoneal Mass: A Case Report

**Authors:** Kazuto Imai, Norihiko Masuda, Tatsuya Hazama, Toshihide Hosomi, Keita Hanada, Takakazu Matsushita, Toshiya Akao

PMC · DOI: 10.1002/iju5.70157 · IJU Case Reports · 2026-02-25

## TL;DR

A case of invasive bladder cancer causing multiple obstructions is reported, highlighting unusual complications and treatment considerations.

## Contribution

This case report highlights an unusual presentation of bladder cancer with rectal and biliary obstruction, emphasizing the importance of diagnostic and therapeutic strategies.

## Key findings

- Bladder cancer can cause rectal, ureteral, and biliary obstructions without retroperitoneal mass.
- Biliary drainage allowed initiation of systemic therapy in the presence of biliary obstruction.
- Enfortumab vedotin use was avoided due to safety concerns in biliary obstruction.

## Abstract

Bladder cancer (BC) is rarely associated with common bile duct (CBD) obstruction. We report a case of BC with peritoneal invasion and rectal involvement complicated by bilateral ureteral and biliary obstruction.

A 77‐year‐old man presented with abdominal pain. Imaging revealed a bladder tumor with suspected muscle invasion, rectal obstruction, and bilateral hydronephrosis. Urothelial carcinoma was confirmed after transurethral resection of the bladder. Following the operation, the patient developed cholangitis with CBD obstruction, and in the absence of direct invasion or mass‐like lesions suggestive of malignant retroperitoneal fibrosis, retroperitoneal extension was considered a possible mechanism. Safety concerns regarding enfortumab vedotin in the setting of biliary obstruction led us to administer pembrolizumab monotherapy.

BC may contribute to biliary obstruction through retroperitoneal processes, underscoring the need for careful diagnostic and therapeutic assessment. Furthermore, biliary drainage enabled the initiation of systemic therapy, highlighting the importance of appropriate supportive intervention.

We report a case of bladder cancer with peritoneal invasion and rectal involvement complicated by bilateral ureteral and biliary obstruction.

## Linked entities

- **Diseases:** bladder cancer (MONDO:0004986), cholangitis (MONDO:0004789), hydronephrosis (MONDO:0005510)

## Full-text entities

- **Genes:** CDX2 (caudal type homeobox 2) [NCBI Gene 1045] {aka CDX-3, CDX2/AS, CDX3}, GATA3 (GATA binding protein 3) [NCBI Gene 2625] {aka HDR, HDRS}, MUC16 (mucin 16, cell surface associated) [NCBI Gene 94025] {aka CA125}, KRT7 (keratin 7) [NCBI Gene 3855] {aka CK7, K2C7, K7, SCL}, KRT20 (keratin 20) [NCBI Gene 54474] {aka CD20, CK-20, CK20, K20, KRT21}, LOC102724197 (inactive glutathione hydrolase 2) [NCBI Gene 102724197] {aka GGT2}, UPK2 (uroplakin 2) [NCBI Gene 7379] {aka UP2, UPII}, NECTIN4 (nectin cell adhesion molecule 4) [NCBI Gene 81607] {aka EDSS1, LNIR, PRR4, PVRL4, nectin-4}, GPT (glutamic--pyruvic transaminase) [NCBI Gene 2875] {aka AAT1, ALT, ALT1, GPT1, SGPT}
- **Diseases:** Cancer (MESH:D009369), adenocarcinoma (MESH:D000230), rectal obstruction (MESH:D012002), abdominal pain (MESH:D015746), CTCAE (MESH:D064420), liver cirrhosis (MESH:D008103), hydronephrosis (MESH:D006869), hepatobiliary enzyme abnormalities (MESH:D004066), ascites (MESH:D001201), hepatic dysfunction (MESH:D008107), CBD obstruction (MESH:D003138), fibrosis (MESH:D005355), retroperitoneal (MESH:D012186), UC (MESH:D014523), Obstruction (MESH:D000402), ureteral and biliary obstruction (MESH:D014517), necrotic (MESH:D009336), BC (MESH:D001749), Retroperitoneal Mass (MESH:C536030), Stevens-Johnson syndrome (MESH:D013262), cholangitis (MESH:D002761), lymph node metastasis (MESH:D008207), gastric or pancreatic cancer (MESH:D013274), impaired renal function (MESH:D007674), biliary obstruction (MESH:D001658), Urachal carcinoma (MESH:C536475), retroperitoneal fibrosis (MESH:D012185), cholangiocarcinoma (MESH:D018281)
- **Chemicals:** pembrolizumab (MESH:C582435), platinum (MESH:D010984), EVP (-), MMAE (MESH:C495575), EV (MESH:C000632577)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12936410/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12936410/full.md

## References

14 references — full list in the complete paper: https://tomesphere.com/paper/PMC12936410/full.md

---
Source: https://tomesphere.com/paper/PMC12936410